New Study Links ERBB4 Receptor to Alzheimer's Disease Progression
A study published in Nature reveals that the ERBB4 receptor plays a crucial role in Alzheimer's progression, offering potential new targets for early drug intervention and cognitive recovery.
A new study published in the journal Nature points to a previously lesser-known mechanism potentially involved in the development of Alzheimer's disease, opening new avenues for future drug therapies.
The Role of the ERBB4 Receptor
Researchers from the Institute for Basic Science in South Korea suggest that the ERBB4 receptor—traditionally linked to brain development and certain types of cancer rather than Alzheimer's—may hold a key role in the disease's progression. The brain operates in a delicate balance between excitation and inhibition. In a healthy brain, the ERBB4 receptor is typically found in inhibitory neurons. However, in mice with Alzheimer's-like pathology, the receptor abnormally appeared in excitatory neurons.
Using genetic engineering, the researchers selectively removed the receptor from these excitatory neurons. This intervention reversed several pathological phenomena in the mice: abnormally high pruning of excitatory synapses was halted, amyloid-beta accumulation decreased, and the mice demonstrated significantly improved cognitive performance.
"The precise course of Alzheimer's development remains incompletely understood, but targeting this receptor could allow early intervention," noted the researchers.
Validating Human Relevance
To bridge the gap between animal models and human pathology, the researchers analyzed brain tissue samples from 450 deceased individuals. The analysis revealed that the expression of ERBB4 in excitatory neurons correlates strongly with Alzheimer's-related pathologies and cognitive decline. While current treatments primarily focus on amyloid-beta and tau proteins with limited efficacy, targeting the ERBB4 mechanism could provide an alternative therapeutic approach even after substantial damage has occurred.
